TVM Life Science Ventures VII is a unique collaboration between TVM Capital Life Science and Lilly to finance and access innovation outside the Lilly walls and as a way to manage risk and share reward. This strategic relationship with Lilly enables the project focused companies of the fund to reach clinical proof of concept efficiently and cost effectively. Each project focused company can choose to work with Chorus, Lilly’s efficient and cost-effective development engine for early to mid-stage molecules. Chorus, which is part of Global External Research and Development at Lilly, designs and executes lean and focused drug development plans that specifically test key scientific hypotheses to progress molecules from candidate selection to clinical proof-of-concept.
Bukwang Pharm. Co. Ltd.
Bukwang Pharm. Co. Ltd. and TVM Capital Life Science announced in December 2013, that both companies signed a global partnership agreement. Bukwang Pharm. Co., Ltd. is a leading Korean pharmaceutical company listed on the Korean Stock Exchange [KRX:003000]. The company has been in business for over 50 years, and achieved US$130 million in sales in 2012. Sales are primarily derived from products licensed from Europe, the United States, and Japan. The company is currently investing significant resources in R&D to create a robust pipeline of preclinical and clinical agents for the treatment of antiviral diseases, gastrointestinal disorders, CNS disorders and metabolic disease.
Korea Drug Development
TVM Capital Life Science entered into an MOU with the Korea Drug Development (“KDDF”) to support Korea’s ability to develop new drugs that meet global standards. The MOU was signed and announced between the KDDF and TVM Capital Life Science during ‘BIO KOREA 2013 International Convention’ in Seoul in September 2013. This MOU is the KDDF’s third global MOU since its inception and the first one with a international Life Science Venture Capital firm. The KDDF’s mandate from the Korean government is to create successful drug development business models in Korea, while developing human resources for sustainable growth and build effective partnerships between government, industry (including the venture capital industry) and academia.